Severe Chronic Obstructive Pulmonary Disease
Conditions
Keywords
weaned tobacco, Has not submitted an exacerbation in the past 3 months
Brief summary
Design studies of nebulization in COPD does not respond adequately to the clinically relevant question: the intervention of administering nebulized bronchodilators at home it is likely to make a profit, compared to the standard optimized treatment as defined by the recommendations of the SPLF, patients with severe COPD (stage III, FEV between 30% and 50% of the theoretical value) and very severe (stage IV, less than 30% of the theoretical value FEV)? The concept of profit in this context is based on criteria of dyspnea, quality of life, use of health system (exacerbations, hospitalizations, prescription of antibiotics and steroids ...).
Interventions
DRUGAtrovent + Bricanyl or Atrovent + Ventoline
3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
DRUGPlacebo
1 capsule lactose during 48 weeks
Sponsors
University Hospital, Tours
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Adult * COPD Patients stage 3 et 4 * Has not submitted an exacerbation in the 3 months preceding the pre-inclusion visit * Weaned from tobacco for at least 6 months * vaccinated against pneumococcal * Have not been included in a pulmonary rehabilitation program during the 6 months preceding the screening visit inclusion * Patient pre-included not showing exacerbation since the pre-inclusion visit
Exclusion criteria
* Patient under nebulizer or has been treated with nebulized bronchodilators at home over the last 6 months * Patient with an indication of oxygen is expected in the coming year * Progressive malignant disease known * Patient under non-invasive ventilation (NIV) for less than 6 months or NIV provided in the following year * Patient known to be colonized by Pseudomonas aeruginosa, A. xylosoxidans, Burkholderia cepacia or Stenotrophomonas maltophilia * Patients with severe cardiovascular disease * Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Score for quality of life, assessed by the questionnaire St Georges | Patients will be followed for the duration of their participation ie 48 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Score for quality of life, assessed by the questionnaire VQ11 | Patients will be followed for the duration of their participation ie 48 weeks |
| Dyspnea score according Medical Research Council | Patients will be followed for the duration of their participation ie 48 weeks |
| Prognostic Score Mortality assessed by the score BODE | Patients will be followed for the duration of their participation ie 48 weeks |
Other
| Measure | Time frame |
|---|---|
| Number of exacerbations | Patients will be followed for the duration of their participation ie 48 weeks |
| Number of hospitalizations | Patients will be followed for the duration of their participation ie 48 weeks |
Countries
France
Outcome results
None listed